J. Tomala

发表

Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death

P. Agostinis, P. Cartron, Abhishek D Garg, 2017, Oncoimmunology.

Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.

V. Šubr, T. Etrych, B. Říhová, 2017, Biomaterials.

Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.

K. Ulbrich, L. Kovář, T. Etrych, 2008, Cancer research.

Doxorubicin Resistance in Mice Cured by Targeted Polymer-Bound Mediated BCL 1-Specific − T-Cell + and Induction of CD 8 Overcoming Immunoescape Mechanisms of BCL 1 Leukemia

K. Ulbrich, L. Kovář, T. Etrych, 2008 .

Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection

Mark S. Anderson, Jamie B. Spangler, Aaron S. Meyer, 2022, bioRxiv.

Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis

J. Mašín, R. Osicka, P. Šebo, 2017, Infection and Immunity.

Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufﬁcient for Lung Infection but Not for Full Virulence of Bordetella pertussis PATHOGEN-HOST CELL MOLECULAR

J. Mašín, R. Osicka, I. Adkins, 2017 .

Bordetella Adenylate Cyclase Toxin Differentially Modulates Toll-Like Receptor-Stimulated Activation, Migration and T Cell Stimulatory Capacity of Dendritic Cells

J. Mašín, P. Šebo, L. Bumba, 2014, PloS one.

IL-7/αIL-7 mAb M25 immunocomplexes expand CD8+ T cells but paradoxically abrogate the antitumor activity of CTLA-4 and PD-1 blockage.

J. Uhlík, M. Kovář, J. Tomala, 2020, Cytokine.

Characterization of Immune Cell Subset Expansion in Response to Therapeutic Treatment in Mice.

Jamie B. Spangler, J. Tomala, 2020, Methods in molecular biology.

Synergistic effect of EMF–BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma

K. Ulbrich, T. Etrych, B. Říhová, 2011, Journal of drug targeting.

Pore‐formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells

O. Cerny, J. Mašín, P. Šebo, 2016, Immunology and cell biology.

The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel

T. Etrych, B. Říhová, M. Šírová, 2017, Journal of controlled release : official journal of the Controlled Release Society.

Pertussis toxin suppresses dendritic cell-mediated delivery of B. pertussis into lung-draining lymph nodes

P. Šebo, O. Staněk, L. Bumba, 2022, PLoS pathogens.

Antitumor activity of IL‐2/anti‐IL‐2 mAb immunocomplexes exerts synergism with that of N‐(2‐hydroxypropyl)methacrylamide copolymer‐bound doxorubicin conjugate due to its low immunosuppressive activity

K. Ulbrich, B. Říhová, M. Šírová, 2011, International journal of cancer.

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

I. Adkins, Zuzana Antošová, M. Šírová, 2022, Frontiers in Immunology.

Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells

I. Adkins, L. Sadílková, R. Spíšek, 2017, Oncoimmunology.

Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally.

B. Říhová, Petra Votavová, M. Kabešová, 2013, ACS chemical biology.

IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?

M. Kovář, J. Tomala, 2016, Oncoimmunology.

In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy1

T. Mrkvan, B. Říhová, M. Kovář, 2009, The Journal of Immunology.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.

Jamie B. Spangler, K. Garcia, A. Ring, 2015, Immunity.

Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy

Jamie B. Spangler, V. Pande, K. Garcia, 2018, The Journal of Immunology.

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

Petra Votavová, M. Kovář, J. Tomala, 2014, Immunology letters.

Delivery of Large Heterologous Polypeptides across the Cytoplasmic Membrane of Antigen-Presenting Cells by the Bordetella RTX Hemolysin Moiety Lacking the Adenylyl Cyclase Domain

J. Michálek, J. Mašín, P. Šebo, 2012, Infection and Immunity.

Delivery of large heterologous polypeptides across the

J. Michálek, J. Mašín, O. Staněk, 2012 .

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells

Zuzana Jiraskova Zakostelska, B. Tomalová, M. Kovář, 2021, eLife.

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling.

V. Šubr, T. Etrych, B. Říhová, 2021, Journal of controlled release : official journal of the Controlled Release Society.

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.

K. Ulbrich, T. Etrych, B. Říhová, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity

Jamie B. Spangler, W. Leonard, O. Vaněk, 2023, bioRxiv.

TITLEEngineering a single-agent cytokine-antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. AUTHORS

Petra Votavová, E. Trotta, J. Tomala, 2018 .

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.

K. Ulbrich, T. Etrych, B. Říhová, 2016, Journal of controlled release : official journal of the Controlled Release Society.